» Articles » PMID: 20028500

Co-infection by Human Immunodeficiency Virus Type 1 (HIV-1) and Human T Cell Leukemia Virus Type 1 (HTLV-1): Does Immune Activation Lead to a Faster Progression to AIDS?

Overview
Journal BMC Infect Dis
Publisher Biomed Central
Date 2009 Dec 24
PMID 20028500
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Recent data have shown that HTLV-1 is prevalent among HIV positive patients in Mozambique, although the impact of HTLV-1 infection on HIV disease progression remains controversial. Our aim was to determine the phenotypic profile of T lymphocytes subsets among Mozambican patients co-infected by HIV and HTLV-1.

Methods: We enrolled 29 patients co-infected by HTLV-1 and HIV (co-infected), 59 patients mono-infected by HIV (HIV) and 16 healthy controls (HC), respectively.For phenotypic analysis, cells were stained with the following fluorochrome-labeled anti-human monoclonal antibodies CD4-APC, CD8-PerCP, CD25-PE, CD62L-FITC, CD45RA-FITC. CD45RO-PE, CD38-PE; being analysed by four-colour flow cytometry.

Results: We initially found that CD4+ T cell counts were significantly higher in co-infected, as compared to HIV groups. Moreover, CD4+ T Lymphocytes from co-infected patients presented significantly higher levels of CD45RO and CD25, but lower levels of CD45RA and CD62L, strongly indicating that CD4+ T cells are more activated under HTLV-1 plus HIV co-infection.

Conclusion: Our data indicate that HTLV-1/HIV co-infected patients progress with higher CD4+ T cell counts and higher levels of activation markers. In this context, it is conceivable that in co-infected individuals, these higher levels of activation may account for a faster progression to AIDS.

Citing Articles

Prevalence of HTLV-1 and Hepatitis B Surface Antigen (HBsAg) Positivity among MSM Attending a Large HIV Treatment Centre in Trinidad.

Edwards R, Todd S, Edwards J, Jack N, Boyce G Viruses. 2024; 16(7).

PMID: 39066331 PMC: 11281644. DOI: 10.3390/v16071169.


Human T-Cell Leukemia Virus Type 1-Related Diseases May Constitute a Threat to the Elimination of Human Immunodeficiency Virus, by 2030, in Gabon, Central Africa.

Oloumbou E, Engone-Ondo J, Mamimandjiami Idam I, Moussavou-Boudzanga P, Mfouo-Tynga I, Mouinga-Ondeme A Viruses. 2022; 14(12).

PMID: 36560812 PMC: 9785256. DOI: 10.3390/v14122808.


HTLV-1 Coinfection among Patients Attending a Large HIV Treatment Centre in Trinidad.

Edwards R, Julien-Serrette K, Edwards J, Boyce G Microorganisms. 2022; 10(11).

PMID: 36363801 PMC: 9692670. DOI: 10.3390/microorganisms10112207.


Dynamics of HIV-1/HTLV-I Co-Infection Model with Humoral Immunity and Cellular Infection.

AlShamrani N, Alshaikh M, Elaiw A, Hattaf K Viruses. 2022; 14(8).

PMID: 36016341 PMC: 9415130. DOI: 10.3390/v14081719.


Human T-Lymphotropic virus type 1 and human immunodeficiency virus co-infection in rural Gabon.

Mouinga-Ondeme A, Boundenga L, Koumba I, Idam Mamimandjiami A, Diane A, Engone-Ondo J PLoS One. 2022; 17(7):e0271320.

PMID: 35867643 PMC: 9307203. DOI: 10.1371/journal.pone.0271320.


References
1.
Bentwich Z, Kalinkovich A, Weisman Z, Grossman Z . Immune activation in the context of HIV infection. Clin Exp Immunol. 1998; 111(1):1-2. PMC: 1904872. DOI: 10.1046/j.1365-2249.1998.00483.x. View

2.
Bartholomew C, Blattner W, Cleghorn F . Progression to AIDS in homosexual men co-infected with HIV and HTLV-I in Trinidad. Lancet. 1987; 2(8573):1469. DOI: 10.1016/s0140-6736(87)91172-x. View

3.
Murakami T, Hattori T, Maeda Y, Matsushita S, Kannagi M, Sagawa K . Immunological and virological status of a hemophiliac infected with human T cell lymphotropic virus type 1 and human immunodeficiency virus type 1, and results of therapy. Int J Hematol. 1991; 54(1):85-90. View

4.
Sodora D, Silvestri G . Immune activation and AIDS pathogenesis. AIDS. 2008; 22(4):439-46. DOI: 10.1097/QAD.0b013e3282f2dbe7. View

5.
Borkow G, Bentwich Z . Chronic immune activation associated with chronic helminthic and human immunodeficiency virus infections: role of hyporesponsiveness and anergy. Clin Microbiol Rev. 2004; 17(4):1012-30, table of contents. PMC: 523563. DOI: 10.1128/CMR.17.4.1012-1030.2004. View